Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 126

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa

Rezzoagli, Chiara, Archetti, Martina, Mignot, Ingrid, Baumgartner, Michael, Kümmerli, Rolf · 2020 · PLOS Biology

Published version of a preprint

Abstract

Antibiotics are losing efficacy due to the rapid evolution and spread of resistance. Treatments targeting bacterial virulence factors have been considered as alternatives because they target virulence instead of pathogen viability, and should therefore exert weaker selection for resistance than conventional antibiotics. However, antivirulence treatments rarely clear infections, which compromises their clinical applications. Here, we explore the potential of combining antivirulence drugs with antibiotics against the opportunistic human pathogen Pseudomonas aeruginosa. We combined two antivirulence compounds (gallium, a siderophore quencher, and furanone C-30, a quorum sensing [QS] inhibitor) together with four clinically relevant antibiotics (ciprofloxacin, colistin, meropenem, tobramycin) in 9×9 drug concentration matrices. We found that drug-interaction patterns were concentration dependent, with promising levels of synergies occurring at intermediate drug concentrations for certain drug pairs. We then tested whether antivirulence compounds are potent adjuvants, especially when treating antibiotic resistant (AtbR) clones. We found that the addition of antivirulence compounds to antibiotics could restore growth inhibition for most AtbR clones, and even abrogate or reverse selection for resistance in five drug combination cases. Molecular analyses suggest that selection against resistant clones occurs when resistance mechanisms involve restoration of protein synthesis, but not when efflux pumps are up-regulated. Altogether, our work provides a first systematic analysis of antivirulence-antibiotic combinatorial treatments and suggests that such combinations have the potential to be both effective in treating infections and in limiting the spread of antibiotic resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.3000805

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 86

  1. GM Rossolini, 2014, Update on the antibiotic resistance crisis, Curr Opin Pharmacol, 18, 56, 10.1016/j.coph.2014.09.006 · DOI · Paper page
  2. World Health Organization (WHO), 2014, Antimicrobial resistance: Global Health Report on Surveillance, Bull World Health Organ
  3. J O’Neill, 2014, Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations, Review on Antimicrobial Resistance
  4. R Laxminarayan, 2016, Access to effective antimicrobials: a worldwide challenge, Lancet, 387, 168, 10.1016/S0140-6736(15)00474-2 · DOI · Paper page
  5. SW Dickey, 2017, Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance., Nat Rev Drug Discov, 16, 1, 10.1038/nrd.2017.23 · DOI · Paper page
  6. D Brown, 2015, Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?, Nat Rev Drug Discov, 14, 821, 10.1038/nrd4675 · DOI · Paper page
  7. RC Allen, 2014, Targeting virulence: can we make evolution-proof drugs?, Nat Rev Microbiol, 12, 300, 10.1038/nrmicro3232 · DOI · Paper page
  8. PF Vale, 2014, Limiting Damage during Infection: Lessons from Infection Tolerance for Novel Therapeutics, PLoS Biol, 12, e1001769, 10.1371/journal.pbio.1001769 · DOI
  9. PF Vale, 2016, Beyond killing., Evol Med Public Heal, 2016, 148, 10.1093/emph/eow012 · DOI
  10. L Ternent, 2015, Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment, J Theor Biol, 372, 1, 10.1016/j.jtbi.2015.02.011 · DOI
  11. M Hentzer, 2003, Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors, EMBO J, 22, 3803, 10.1093/emboj/cdg366 · DOI · Paper page
  12. E Banin, 2008, The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent, Proc Natl Acad Sci, 105, 16761, 10.1073/pnas.0808608105 · DOI · Paper page
  13. Z Zeng, 2008, Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of Pseudomonas aeruginosa, Appl Microbiol Biotechnol, 79, 119, 10.1007/s00253-008-1406-5 · DOI · Paper page
  14. TH Jakobsen, 2012, Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing, Antimicrob Agents Chemother, 56, 2314, 10.1128/AAC.05919-11 · DOI · Paper page
  15. G Michaud, 2016, Overcoming antibiotic resistance in Pseudomonas aeruginosa biofilms using glycopeptide dendrimers., Chem Sci, 7, 166, 10.1039/C5SC03635F · DOI
  16. CH Goss, 2018, Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections, Sci Transl Med, 10, eaat7520, 10.1126/scitranslmed.aat7520 · DOI · Paper page
  17. DR Kirienko, 2019, Novel Pyoverdine Inhibitors Mitigate Pseudomonas aeruginosa Pathogenesis., Front Microbiol., 9, 3317, 10.3389/fmicb.2018.03317 · DOI
  18. EBM Breidenstein, 2011, Pseudomonas aeruginosa: all roads lead to resistance, Trends Microbiol, 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
  19. C Rezzoagli, 2020, Harnessing bacterial interactions to manage infections: a review on the opportunistic pathogen Pseudomonas aeruginosa as a case example, J Med Microbiol, 69, 147, 10.1099/jmm.0.001134 · DOI
  20. M Hentzer, 2002, Inhibition of Quorum Sensing in Pseudomonas aeruginosa Biofilm Bacteria by a Halogenated Furanone Compound, Microbiology, 148, 87, 10.1099/00221287-148-1-87 · DOI · Paper page
  21. TB Rasmussen, 2005, Screening for Quorum-Sensing Inhibitors (QSI) by Use of a Novel Genetic System, the QSI Selector., J Bacteriol, 187, 1799, 10.1128/JB.187.5.1799-1814.2005 · DOI · Paper page
  22. T Defoirdt, 2018, Quorum-Sensing Systems as Targets for Antivirulence Therapy, Trends Microbiol, 26, 313, 10.1016/j.tim.2017.10.005 · DOI · Paper page
  23. Y Kaneko, 2007, The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity, J Clin Invest, 117, 877, 10.1172/JCI30783 · DOI · Paper page
  24. DJ Smith, 2013, Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis, Eur Respir J, 42, 1723, 10.1183/09031936.00124012 · DOI
  25. F Imperi, 2013, Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity, Proc Natl Acad Sci, 110, 7458, 10.1073/pnas.1222706110 · DOI
  26. K DeLeon, 2009, Gallium Maltolate Treatment Eradicates Pseudomonas aeruginosa Infection in Thermally Injured Mice, Antimicrob Agents Chemother, 53, 1331, 10.1128/AAC.01330-08 · DOI
  27. AB Kelson, 2013, Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms, Curr Opin Pharmacol, 13, 707, 10.1016/j.coph.2013.07.001 · DOI · Paper page
  28. C Bonchi, 2014, Repurposing of gallium-based drugs for antibacterial therapy, BioFactors, 40, 303, 10.1002/biof.1159 · DOI
  29. S Hijazi, 2017, Gallium-Protoporphyrin IX Inhibits Pseudomonas aeruginosa Growth by Targeting Cytochromes, Front Cell Infect Microbiol, 7, 1, 10.3389/fcimb.2017.00012 · DOI
  30. AJ Manny, 1997, Reinvestigation of the sulfuric acid-catalysed cyclisation of brominated 2-alkyllevulinic acids to 3-alkyl-5-methylene-2(5H)-furanones., Tetrahedron, 53, 15813, 10.1016/S0040-4020(97)10034-5 · DOI
  31. M Manefield, 1999, Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein., Microbiology, 145, 283, 10.1099/13500872-145-2-283 · DOI · Paper page
  32. R Kümmerli, 2009, Phenotypic plasticity of a cooperative behaviour in bacteria, J Evol Biol, 22, 589, 10.1111/j.1420-9101.2008.01666.x · DOI · Paper page
  33. P Visca, 2007, Pyoverdine siderophores: from biogenesis to biosignificance, Trends Microbiol, 15, 22, 10.1016/j.tim.2006.11.004 · DOI · Paper page
  34. C Rezzoagli, 2018, Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in Pseudomonas aeruginosa., Evol Med Public Heal, 1, 246
  35. M Bassetti, 2018, How to manage Pseudomonas aeruginosa infections., Drugs Context., 7, 212527, 10.7573/dic.212527 · DOI · Paper page
  36. A Rehman, 2019, Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem, J Med Microbiol, 68, 1, 10.1099/jmm.0.000873 · DOI · Paper page
  37. K Poole, 2018, Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression, Antimicrob Agents Chemother, 40, 2021, 10.1128/AAC.40.9.2021 · DOI · Paper page
  38. N Jochumsen, 2016, The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions, Nat Commun, 7, 13002, 10.1038/ncomms13002 · DOI
  39. Y Tsutsumi, 2013, Identification of Novel Genes Responsible for Overexpression of ampC in Pseudomonas aeruginosa PAO1, Antimicrob Agents Chemother, 57, 5987, 10.1128/AAC.01291-13 · doi:10.1128/aac.01291-13
  40. C Muller, 2011, A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and beta-Lactams in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 55, 1211, 10.1128/AAC.01252-10 · doi:10.1128/aac.01252-10
  41. L Zhang, 2008, Involvement of a novel efflux system in biofilm-specific resistance to antibiotics, J Bacteriol, 190, 4447, 10.1128/JB.01655-07 · DOI · Paper page
  42. J Quale, 2006, Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates, Antimicrob Agents Chemother, 50, 1633, 10.1128/AAC.50.5.1633-1641.2006 · DOI · Paper page
  43. Y ping Pan, 2016, Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa., Arch Microbiol, 198, 565, 10.1007/s00203-016-1215-7 · DOI · Paper page
  44. A Bolard, 2017, Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 62, e01835, 10.1128/AAC.01835-17 · DOI
  45. C López-Causapé, 2018, Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting, Antimicrob Agents Chemother, 62, e02583, 10.1128/AAC.02583-17 · DOI
  46. K Poole, 2018, Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression, Antimicrob Agents Chemother, 40, 2021, 10.1128/AAC.40.9.2021 · DOI · Paper page
  47. PG Higgins, 2003, Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa., Int J Antimicrob Agents, 21, 409, 10.1016/S0924-8579(03)00009-8 · DOI
  48. AK Miller, 2011, PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients, Antimicrob Agents Chemother, 55, 5761, 10.1128/AAC.05391-11 · DOI · Paper page
  49. JY Lee, 2016, Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa., Sci Rep, 6, 25543, 10.1038/srep25543 · DOI
  50. K Barrow, 2009, Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 53, 5150, 10.1128/AAC.00893-09 · DOI
  51. F Sanz-garcía, 2018, Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam, Antimicrob Agents Chemother, 62, e01379, 10.1128/AAC.01379-18 · DOI
  52. GL Winsor, 2015, Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database, Nucleic Acids Res, 44, D646, 10.1093/nar/gkv1227 · DOI · Paper page
  53. JF Acar, 2000, Antibiotic synergy and antagonism., Med Clin North Am, 84, 1391, 10.1016/S0025-7125(05)70294-7 · DOI
  54. J Lehár, 2009, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat Biotechnol, 27, 659, 10.1038/nbt.1549 · DOI · Paper page
  55. MA Alkawash, 2006, Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms, Apmis, 114, 131, 10.1111/j.1600-0463.2006.apm_356.x · DOI · Paper page
  56. J Luo, 2017, Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model., PLoS ONE., 12, e0176883, 10.1371/journal.pone.0176883 · DOI · Paper page
  57. J Turnidge, 2007, Setting and revising antibacterial susceptibility breakpoints, Clin Microbiol Rev, 20, 391, 10.1128/CMR.00047-06 · DOI · Paper page
  58. HS Sader, 2017, Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States., Antimicrob Agents Chemother, 61, e02252, 10.1128/AAC.02252-16 · DOI
  59. R Chait, 2007, Antibiotic interactions that select against resistance, Nature, 446, 668, 10.1038/nature05685 · DOI · Paper page
  60. M Hegreness, 2008, Accelerated evolution of resistance in multidrug environments, Proc Natl Acad Sci, 105, 13977, 10.1073/pnas.0805965105 · DOI · Paper page
  61. M Baym, 2016, Multidrug evolutionary strategies to reverse antibiotic resistance, Science, 351, aad3292, 10.1126/science.aad3292 · DOI · Paper page
  62. T Maeda, 2012, Quorum quenching quandary: resistance to antivirulence compounds., ISME J, 6, 493, 10.1038/ismej.2011.122 · DOI · Paper page
  63. N Wale, 2017, Resource limitation prevents the emergence of drug resistance by intensifying within-host competition, Proc Natl Acad Sci, 114, 13774, 10.1073/pnas.1715874115 · DOI
  64. B Mellbye, 2011, The sociomicrobiology of antivirulence drug resistance: a proof of concept., MBio, 2, e00131, 10.1128/mBio.00131-11 · DOI · Paper page
  65. JP Gerdt, 2014, Competition Studies Confirm Two Major Barriers That Can Preclude the Spread of Resistance to Quorum-Sensing Inhibitors in Bacteria., ACS Chem Biol, 9, 2291, 10.1021/cb5004288 · DOI
  66. NM Vega, 2014, Collective antibiotic resistance: Mechanisms and implications, Curr Opin Microbiol, 21, 28, 10.1016/j.mib.2014.09.003 · DOI · Paper page
  67. MA Fischbach, 2011, Combination therapies for combating antimicrobial resistance, Curr Opin Microbiol, 14, 519, 10.1016/j.mib.2011.08.003 · DOI · Paper page
  68. LL Silver, 2011, Challenges of Antibacterial Discovery., Clin Microbiol Rev, 24, 71, 10.1128/CMR.00030-10 · DOI · Paper page
  69. B Tepekule, 2017, Modeling antibiotic treatment in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing, and mono-drug therapies., PLoS Comput Biol., 13, e1005745, 10.1371/journal.pcbi.1005745 · DOI
  70. M Tyers, 2019, Drug combinations: a strategy to extend the life of antibiotics in the 21st century, Nat Rev Microbiol, 17, 141, 10.1038/s41579-018-0141-x · DOI · Paper page
  71. T Cihlar, 2016, Current status and prospects of HIV treatment., Curr Opin Virol, 18, 50, 10.1016/j.coviro.2016.03.004 · DOI · Paper page
  72. AM Ginsberg, 2007, Challenges in tuberculosis drug research and development, Nat Med, 13, 290, 10.1038/nm0307-290 · DOI · Paper page
  73. L Zhou, 2014, The Social Biology of Quorum Sensing in a Naturalistic Host Pathogen System, Curr Biol, 24, 2417, 10.1016/j.cub.2014.08.049 · DOI
  74. C Rezzoagli, 2019, In vivo microscopy reveals the impact of Pseudomonas aeruginosa social interactions on host colonization, ISME J, 13, 2403, 10.1038/s41396-019-0442-8 · DOI
  75. CR Proctor, 2020, Furanone quorum-sensing inhibitors with potential as novel therapeutics against Pseudomonas aeruginosa, J Med Microbiol, 69, 195, 10.1099/jmm.0.001144 · DOI
  76. K-H Choi, 2006, mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa, Nat Protoc, 1, 153, 10.1038/nprot.2006.24 · DOI · Paper page
  77. Ö Özkaya, 2018, Cheating on Cheaters Stabilizes Cooperation in Pseudomonas aeruginosa, Curr Biol, 26, 2070, 10.1016/j.cub.2018.04.093 · DOI
  78. PS Ocampo, 2014, Antagonism between bacteriostatic and bactericidal antibiotics is prevalent, Antimicrob Agents Chemother, 58, 4573, 10.1128/AAC.02463-14 · DOI · Paper page
  79. JR Morones-Ramirez, 2013, Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria., Sci Transl Med., 5, 190ra81, 10.1126/scitranslmed.3006276 · DOI · Paper page
  80. DY Baeder, 2016, Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models., Philos Trans R Soc B Biol Sci, 371, 20150294, 10.1098/rstb.2015.0294 · DOI
  81. C Barbosa, 2018, Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model., PLoS Biol, 16, e2004356, 10.1371/journal.pbio.2004356 · DOI
  82. AM Bolger, 2014, Trimmomatic: a flexible trimmer for Illumina sequence data, Bioinformatics, 30, 2114, 10.1093/bioinformatics/btu170 · DOI · Paper page
  83. P Danecek, 2011, The variant call format and VCFtools, Bioinformatics, 27, 2156, 10.1093/bioinformatics/btr330 · DOI · Paper page
  84. A Ross-Gillespie, 2007, Frequency dependence and cooperation: theory and a test with bacteria, Am Nat, 170, 331, 10.1086/519860 · DOI · Paper page
  85. R Development Core Team, 2013, R: A language and environment for statistical computing.
  86. C Ritz, 2015, Dose-Response Analysis Using R., PLoS ONE., 10, e0146021, 10.1371/journal.pone.0146021 · DOI · Paper page

Cited by

See all 126

Metadata

Authors
Rezzoagli, C., Archetti, M., Mignot, I., Baumgartner, M., & Kümmerli, R.
Venue
PLOS Biology
Published
2020-08-18
Volume
18
Issue
8
Pages
e3000805
ISSN
1545-7885
Cited by
126
References
5
Language
en
Funders
  • H2020 European Research Council (681295)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_182499)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.